Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVER 001

Next Previous
Drug Profile

EVER 001

Alternative Names: EVER-001; SN-1011; XNW-1011

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sinovent
  • Developer Everest Medicines; Evopoint Biosciences; SinoMab Bioscience Ltd
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Neuromyelitis optica; Pemphigus vulgaris
  • Phase I/II Membranous glomerulonephritis
  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus
  • No development reported B-cell lymphoma

Most Recent Events

  • 09 Jun 2025 Efficacy and adverse events data from a phase I/II trial in Membranous glomerulonephritis released by Everest Medicines
  • 05 Feb 2025 phase-I development is still ongoing in Systemic-lupus-erythematosus (In volunteers) in China (PO, Capsule)
  • 04 Dec 2024 Interim adverse events data from a phase I/II trial in Membranous glomerulonephritis released by Everest Medicines

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top